Actos Bladder Cancer Lawsuits Filed After FDA Issues Warning Regarding Increased Risk of Bladder Cancer from Using the Diabetes Drug Actos
Actos (pioglitazone) is a diabetes drug marketed by Takeda Pharmaceuticals that has been linked to increased risk of bladder cancer for years and was recently pulled from the market in a number of countries. Actos was recalled in France because of the increased bladder cancer risk. Although the FDA has issued an Actos bladder cancer warning, the drug remains in use in the United States. Many of the persons using Actos who developed bladder cancer have now filed one of thousands of Actos bladder cancer lawsuits.
The market for diabetes drugs is huge, with the best selling diabetes drug typically exceeding annual sales of $2 billion just in the United States. Actos, recently the most popular diabetes drug in the U.S. had annual sales of more than $6 billion. This is despite early knowledge that Actos could increase the risk of bladder cancer - Actos bladder cancer was detected during initial animal testing - and that Actos bladder cancer rates were known to be higher than the incidence of bladder cancer for other diabetes medications. Just as the diabetes drug Avandia, taken off the market for its role in causing heart attacks, strokes and other forms of cardiovascular disease, resulted in thousands of lawsuits, so could Actos bladder cancer. Given that more than 2 million people filled Actos or Actoplus prescriptions in 2010 in the United States, the forthcoming Actos bladder cancer lawsuits will likely be in the thousands.
This website provides information about Actos, bladder cancer, when it was known that Actos could increase the risk of bladder cancer, the Actos bladder cancer FDA warning and what rights you and your family may have if you or a loved one developed bladder cancer after taking Actos.